Alidornase alfa

Drug Profile

Alidornase alfa

Alternative Names: AIR DNAse™; PRX 110

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Protalix BioTherapeutics
  • Class Recombinant proteins
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 03 Jan 2017 Interim efficacy data from a phase II trial in Cystic fibrosis released by Protalix BioTherapeutics
  • 22 Dec 2016 Protalix BioTherapeutics completes enrolment in its phase II trial for Cystic fibrosis in Israel
  • 09 May 2016 Protalix BioTherapeutics files for a phase II protocol of PRX 110 for treatment of patients with Cystic fibrosis in Israel before May 2016 prior to May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top